The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events
Open accessAbstract
BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The presence of an abdominal aortic aneurysm represents a riskequivalent condition for CAD and is associated with age, male gender, personal history of atherosclerotic CVD, smoking, hypertension, and dyslipidaemia [519]; in contrast, diabetic patients are at decreased risk.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [519]
Experimental — accuracy not yet measuredIn the citing paper
“In an intriguing post hoc analysis of the AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study), investigators observed that statin therapy remained effective at mitigating risk in individuals with elevated high-sensitivity C-reactive protein but low LDL-C (28)”
From Triglycerides and residual atherosclerotic risk (2021) · cites this paper as [28]
In the citing paper
“The presence of an abdominal aortic aneurysm represents a riskequivalent condition for CAD and is associated with age, male gender, personal history of atherosclerotic CVD, smoking, hypertension, and dyslipidaemia [519]; in contrast, diabetic patients are at decreased risk.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [519]
In the citing paper
“The presence of an abdominal aortic aneurysm represents a riskequivalent condition for CAD and is associated with age, male gender, personal history of atherosclerotic CVD, smoking, hypertension, and dyslipidaemia [519]; in contrast, diabetic patients are at decreased risk.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [519]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952
Cited by
Sorted by citations
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationInflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationPearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,796
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citationC-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Self-citationC-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citationRidker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
Self-citationInflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Self-citationPLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Pathophysiology of coronary artery disease
Libby, P., & Theroux, P. (2005) · Circulation · doi:10.1161/circulationaha.105.537878 · Cited by 1,965
Primary Prevention of Ischemic Stroke
Goldstein, L. B., Adams, R. J., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., et al. (2006) · Stroke · doi:10.1161/01.str.0000223048.70103.f1 · Cited by 1,376
Inflammation as a Cardiovascular Risk Factor
Willerson, J. T., & Ridker, P. M. (2004) · Circulation · doi:10.1161/01.cir.0000129535.04194.38 · Cited by 1,304
Self-citationPleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,274
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
Inflammation and cardiovascular disease mechanisms
Libby, P. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.456s · Cited by 1,114
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Self-citationRidker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002
Self-citationInterleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046
Obesity, inflammation, and atherosclerosis
Rocha, V. Z., & Libby, P. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.55 · Cited by 994
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Packard, R. R. S., & Libby, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.097360 · Cited by 925
Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T. Y., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 953
Self-citationAnti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 930
Self-citationPrimary Prevention of Ischemic Stroke
Goldstein, L. B., Adams, R. J., Becker, K. J., Furberg, C. D., Gorelick, P. B., Hádemenos, G. J., Hill, M., Howard, G., Howard, V. J., Jacobs, B. S., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 902
Tonelli, M. A., Sacks, F. M., Arnold, M., Moyé, L. A., Davis, B. R., & Pfeffer, M. A. (2008) · Circulation · doi:10.1161/circulationaha.107.727545 · Cited by 821
Inflammation in Atherosclerosis: Transition From Theory to Practice
Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0706 · Cited by 799
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Self-citationOberg, B. P., McMenamin, E., Lucas, F. L., McMonagle, E., Morrow, J. D., Ikizler, T. A., & Himmelfarb, J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00465.x · Cited by 780
Race and Gender Differences in C-Reactive Protein Levels
Khera, A., McGuire, D. K., Murphy, S. A., Stanek, H. G., Das, S. R., Vongpatanasin, W., Wians, F. H., Grundy, S. M., & de Lemos, J. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.051 · Cited by 773
Novel Clinical Markers of Vascular Wall Inflammation
Blake, G. J., & Ridker, P. M. (2001) · Circulation Research · doi:10.1161/hh2101.099270 · Cited by 756
Self-citationRidker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Self-citationAmarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Atherothrombosis and High-Risk Plaque
Fuster, V., Moreno, P., Fayad, Z. A., Corti, R., & Badimón, J. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.074 · Cited by 757
Inflammatory bio‐markers and cardiovascular risk prediction
Blake, G., & Ridker, P. M. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01019.x · Cited by 699
Self-citationSimvastatin Attenuates Plaque Inflammation
Tahara, N., Kai, H., Ishibashi, M., Nakaura, H., Kaida, H., Baba, K., Hayabuchi, N., & Imaizumi, T. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.069 · Cited by 655
Ridker, P. M., Wilson, P. W. F., & Grundy, S. M. (2004) · Circulation · doi:10.1161/01.cir.0000132467.45278.59 · Cited by 645
Self-citationBiomarkers in Acute Cardiac Disease
Jaffe, A. S., Babuin, L., & Apple, F. S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.056 · Cited by 643
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk
Ridker, P. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.052 · Cited by 635
Self-citationBallantyne, C. M., Hoogeveen, R. C., Bang, H., Coresh, J., Folsom, A. R., HEISS, G. M., & Sharrett, A. R. (2004) · Circulation · doi:10.1161/01.cir.0000116763.91992.f1 · Cited by 611
Inflammation and atherosclerosis: role of C-Reactive protein in risk assessment
Libby, P., & Ridker, P. M. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.006 · Cited by 601
Self-citationStatins for Prevention of Cardiovascular Disease in Adults
Chou, R., Dana, T., Blazina, I., Daeges, M., & Jeanne, T. L. (2016) · JAMA · doi:10.1001/jama.2015.15629 · Cited by 570
Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target
Golia, E., Limongelli, G., Natale, F., Fimiani, F., Maddaloni, V., Pariggiano, I., Bianchi, R., Crisci, M., D’Acierno, L., Giordano, R. C., et al. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0435-z · Cited by 572
Ford, D. E., & Erlinger, T. P. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.1010 · Cited by 544
Multimorbidity in chronic disease: impact on health care resources and costs
McPhail, S. (2016) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s97248 · Cited by 555
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Statin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. O. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 526
Inflammation and Infections as Risk Factors for Ischemic Stroke
Lindsberg, P. J., & Grau, A. (2003) · Stroke · doi:10.1161/01.str.0000089015.51603.cc · Cited by 519
Ridker, P. M., & Cook, N. R. (2004) · Circulation · doi:10.1161/01.cir.0000125690.80303.a8 · Cited by 516
Self-citationThe effect of including C-reactive protein in cardiovascular risk prediction models for women
Cook, N. R., Buring, J. E., & Ridker, P. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00128 · Cited by 504
O’Connor, M.-F., Bower, J. E., Cho, H. J., Creswell, J. D., Dimitrov, S., Hamby, M. E., Hoyt, M. A., Martin, J. L., Robles, T. F., Sloan, E. K., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.04.005 · Cited by 500
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 500
High-Sensitivity C-Reactive Protein and Cardiovascular Disease
Yousuf, O. K., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., Blumenthal, R. S., & Budoff, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.016 · Cited by 505
Metabolic syndrome: Definition, pathophysiology, and mechanisms
Miranda, P. J., DeFronzo, R. A., Califf, R. M., & Guyton, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.013 · Cited by 486
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy
Shishehbor, M. H., Aviles, R. J., Brennan, M.-L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F., Penn, M. S., Sprecher, D. L., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1675 · Cited by 464
High-sensitivity C-reactive protein
Bassuk, S. S., Rifai, N., & Ridker, P. M. (2004) · Current Problems in Cardiology · doi:10.1016/s0146-2806(04)00074-x · Cited by 493
Self-citationInflammatory cytokines in atherosclerosis: current therapeutic approaches
Tousoulis, D., Oikonomou, E. K., Economou, E. K., Crea, F., & Kaski, J. C. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv759 · Cited by 465
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Meshkani, R., & Adeli, K. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.018 · Cited by 470
Bifidobacterium infantis35624 modulates host inflammatory processes beyond the gut
Groeger, D., O’Mahony, L., Murphy, E. F., Bourke, J. F., Dinan, T. G., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2013) · Gut Microbes · doi:10.4161/gmic.25487 · Cited by 448
C-Reactive Protein: A Simple Test to Help Predict Risk of Heart Attack and Stroke
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000093381.57779.67 · Cited by 448
Self-citationNicklas, B. J., Ambrosius, W., Messier, S. P., Miller, G. D., Penninx, B. W., Loeser, R. F., Palla, S., Bleecker, E., & Pahor, M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.4.544 · Cited by 443
Köhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432
Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
Ridker, P. M., Brown, N. J., Vaughan, D. E., Harrison, D. G., & Mehta, J. L. (2004) · Circulation · doi:10.1161/01.cir.0000133444.17867.56 · Cited by 420
Self-citationInflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes
Donath, M. Y., St�rling, J., Maedler, K., & Mandrup-Poulsen, T. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0450-y · Cited by 422
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000100688.17280.e6 · Cited by 424
Self-citationEndothelium-Dependent Effects of Statins
Wolfrum, S., Jensen, K. S., & Liao, J. K. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000063385.12476.a7 · Cited by 416
Ridker, P. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.037 · Cited by 414
Self-citationArad, Y., Spadaro, L. A., Roth, M., Newstein, D., & Guerci, A. D. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.089 · Cited by 414
Sex as a Biological Variable in Atherosclerosis
Man, J. J., Beckman, J. A., & Jaffe, I. Z. (2020) · Circulation Research · doi:10.1161/circresaha.120.315930 · Cited by 416
Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways
Shishehbor, M. H., Brennan, M., Aviles, R. J., Fu, X., Penn, M. S., Sprecher, D. L., & Hazen, S. L. (2003) · Circulation · doi:10.1161/01.cir.0000080895.05158.8b · Cited by 403
Kinlay, S., Schwartz, G. G., OLSSON, A. G., Rifai, N., Leslie, S. J., Sasiela, W. J., Szarek, M. J., Libby, P., & Ganz, P. (2003) · Circulation · doi:10.1161/01.cir.0000091404.09558.af · Cited by 403
Self-citationKuo, H., Yen, C., Chang, C., Kuo, C.-K., Chen, J.-H., & Sorond, F. A. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70099-5 · Cited by 409
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease
Myers, G. L., Rifai, N., Tracy, R. P., Roberts, W. L., Alexander, R. W., Biasucci, L. M., Catravas, J. D., Cole, T. G., Cooper, G. R., Khan, B. V., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148980.87579.5e · Cited by 406
Self-citationThe ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study
Tang, T. Y., Howarth, S. P. S., Miller, S. R., Graves, M. J., Patterson, A. J., U-King-Im, J.-M., Li, Z. Y., Walsh, S. R., Brown, A. P., Kirkpatrick, P. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.018 · Cited by 388
Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.649939 · Cited by 385
Self-citationAssociations Between Cardiorespiratory Fitness and C-Reactive Protein in Men
Church, T. S., Barlow, C. E., Earnest, C. P., Kampert, J. B., Priest, E. L., & Blair, S. N. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000036611.77940.f8 · Cited by 383
Rezaie-Majd, A., Maca, T., Bucek, R. A., Valent, P., Müller, M. R., Husslein, P. W., Kashanipour, A., Minar, E., & Baghestanian, M. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000022694.16328.cc · Cited by 380
C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease
Luc, G., Bard, J., Juhan-Vague, I., Ferrières, J., Evans, A., Amouyel, P., Arveiler, D., Fruchart, J., & Ducimetière, P. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000079512.66448.1d · Cited by 382
Monocytes in Coronary Artery Disease and Atherosclerosis
Ghattas, A., Griffiths, H. R., Devitt, A., Lip, G. Y. H., & Shantsila, E. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.043 · Cited by 387
Primary Prevention of Ischemic Stroke
Goldstein, L. B., Adams, R. J., Becker, K. J., Furberg, C. D., Gorelick, P. B., Hádemenos, G. J., Hill, M., Howard, G., Howard, V. J., Jacobs, B. S., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.163 · Cited by 374
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
Self-citationC-reactive protein and other inflammatory risk markers in acute coronary syndromes
Blake, G. J., & Ridker, P. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02953-4 · Cited by 371
Self-citationBiomarkers of inflammation and progression of chronickidney disease
Tonelli, M. A., Sacks, F. M., Pfeffer, M. A., Jhangri, G. S., & Curhan, G. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00398.x · Cited by 358
Inflammatory biomarkers in coronary artery disease
Zakynthinos, E. G., & Pappa, N. (2009) · Journal of Cardiology · doi:10.1016/j.jjcc.2008.12.007 · Cited by 363
Folsom, A. R., Chambless, L. E., Ballantyne, C. M., Coresh, J., HEISS, G. M., Wu, K. K., Boerwinkle, E., Mosley, T. H., Sorlie, P. D., Diao, G., et al. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.13.1368 · Cited by 357
Statins as anti-inflammatory agents
Weitz‐Schmidt, G. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02077-1 · Cited by 356
Simvastatin Lowers C-Reactive Protein Within 14 Days
Plenge, J. K., Hernandez, T. L., Weil, K. M., Poirier, P., Grunwald, G. K., Marcovina, S. M., & Eckel, R. H. (2002) · Circulation · doi:10.1161/01.cir.0000029743.68247.31 · Cited by 354
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352
Inflammation in Atherosclerosis and Implications for Therapy
Paoletti, R., Gotto, A. M., & Hajjar, D. P. (2004) · Circulation · doi:10.1161/01.cir.0000131514.71167.2e · Cited by 348
Self-citationEffects of Fluticasone on Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease
Sin, D. D., Lacy, P., York, E. L., & Man, S. F. P. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-543oc · Cited by 346
Anti-inflammatory and immunomodulatory effects of statins
Blanco‐Colio, L. M., Tuñón, J., Martı́n-Ventura, J. L., & Egido, J. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00744.x · Cited by 347
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Jain, A. K., & Feng, J. (2008) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2008.242 · Cited by 341
Metadata
- Authors
- Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of North Texas Health Science Center (US)
- Wilford Hall Ambulatory Surgical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-06-28
- Volume
- 344
- Issue
- 26
- Pages
- 1959-1965
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2316243284
- Cited by
- 1,557
- References
- 27
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
- FWCI
- 158.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Doris Duke Charitable Foundation
- American Heart Association
- Fondation Leducq
- National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
- MeSH terms
- Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
